Bringing antibodies from pre-clinical studies to human trials requires humanization， but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease， the most efficacious antibodies should work both intra- and extracellularly. Thus， changes which impact uptake or antibody binding will affect antibody efficacy.

Alzheimer's disease，Antibody engineering，Immunotherapy，Neuroblastoma，Neuron，Tau protein，Vaccine develop